Heron Therapeutics Review: solutions for oncology and postoperative recovery
Heron Therapeutics (NASDAQ: HRTX) - San Diego-based biotechnology company, founded in the USA in 1983. Business is focused on helping patients, undergoing chemotherapy, and relief of postoperative pain. In the distant past, the company's shares were more expensive 1000 $ for pike, and now dropped to 10-12 $. Where the money comes from Commercial business strategy is focused on addressing the unmet needs of different groups of patients and is now engaged in research in the field of oncology and surgery.. The company has already brought several drugs to the U.S. market to relieve postoperative pain and relieve symptoms., caused by different courses of chemotherapy. Product Development Portfolio To date, Heron Therapeutics has successfully commercialized three of its products. Zynrelef. For the first time 72 hours relieves pain in adult patients, who have undergone major knee surgery. Approved by the Food and Drug Administration (FDA) 1 July 2021 and became an alternative to traditional opioids, the use of which is associated with the risk of addiction. Approved in 31 European country. Cinvanti and Sustol. Drugs for adult patients with cancer. Prevents nausea & vomiting, caused by the passage of primary and repeated courses of chemotherapy of varying degrees of aggressiveness. The company has two drugs for adults at the clinical stage of development: HTX-034 to relieve postoperative pain in the first 5-7 days and HTX-019, which prevents bouts of nausea and vomiting in patients, who have undergone surgery. For the latter, it is planned to apply for FDA approval in the fourth quarter of 2021.. Что плохого Коронавирус наносит ответный удар. Last year, the pandemic and lockdowns significantly hurt the company's business.: medical facilities were closed and patients simply could not get their appointments from doctors., prescription drug manufacturers suffered losses. Сейчас ситуация с вакцинацией и мерами профилактики …
Heron Therapeutics Review: solutions for oncology and postoperative recovery Read more